Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)

Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication

PALO ALTO, Calif., May 16, 2018 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the devel... Biopharmaceuticals, Licensing, Distribution Eiger BioPharmaceuticals, Merck, Lonafarnib, Progeria Syndrome

Source: HSMN NewsFeed - May 16, 2018 Category: Pharmaceuticals Source Type: news